ArticleFrontiers in immunology2020
Genetic Engineering of the Kidney to Permanently Silence MHC Transcripts During
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- The Effect of Hypothermic Machine Perfusion to Ameliorate Ischemia-Reperfusion Injury in Donor Organs.Frontiers in immunology · 2022Pooled it
- Acellular Normothermic Machine Perfusion Does not Exacerbate Acute Rejection in Rodent Vascularized Composite Allografts.Transplantation direct · 2026Article
- Improving outcomes in kidney transplantation through advances in donor organ perfusion.Nature reviews. Nephrology · 2025Review
- Beyond preservation: future machine perfusion for liver assessment and repair.Nature reviews. Gastroenterology & hepatology · 2025Review
- LMP2A-Targeting CAR-T Cells Equipped With Inducible IL-18 to Address EBV-Associated Malignancies.HLA · 2025Article
- Normothermic Kidney Perfusion: Current Status and Future Perspectives.Kidney international reports · 2025Review
- Ex vivo machine perfusion as a platform for lentiviral gene delivery in rat livers.Gene therapy · 2025Article
- Evolving adeno-associated viruses for gene transfer to the kidney via cross-species cycling of capsid libraries.Nature biomedical engineering · 2025Article
- Designer Organs: Ethical Genetic Modifications in the Era of Machine Perfusion.Annual review of biomedical engineering · 2025Review
- Delivery of a Muscle-Targeted Adeno-Associated Vector ViaTransplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Organ preservation: current limitations and optimization approaches.Frontiers in medicine · 2025Review
- Enhanced Kidney Targeting and Distribution of Tubuloids During Normothermic Perfusion.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Gene therapy and kidney diseases.Molecular therapy. Methods & clinical development · 2024Review
- A new era in the science and care of kidney diseases.Nature reviews. Nephrology · 2024Review
- Review
- Human PD-L1 overexpression decreases xenogeneic human T-cell immune responses towards porcine kidneys.Frontiers in immunology · 2024Article
- Comparative analysis of swine leukocyte antigen gene diversity in Göttingen Minipigs.Frontiers in immunology · 2024Article
- Heart immunoengineering by lentiviral vector-mediated genetic modification during normothermicFrontiers in immunology · 2024Article
- Downregulation of Swine Leukocyte Antigen Expression Decreases the Strength of Xenogeneic Immune Responses towards Renal Proximal Tubular Epithelial Cells.International journal of molecular sciences · 2023Article
- MHC Class I Masking to Prevent AMR in a Porcine Kidney Transplantation Model in Alloimmunized Recipients.Transplantation direct · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organ gene therapy represents a promising tool to correct diseases or improve graft survival after transplantation. Polymorphic variation of the major histocompatibility complex (MHC) antigens remains a major obstacle to long-term graft survival after transplantation. Previously, we demonstrated that MHC-silenced cells are protected against allogeneic immune responses. We also showed the feasibility to silence MHC in the lung. Here, we aimed at the genetic engineering of the kidney toward permanent silencing of MHC antigens in a rat model. We constructed a sub-normothermic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.